“The program itself saved my life,” he says. “Without a doubt (if not for the program) I’m sure I would be dead … The ...
Schizophrenia is a serious psychiatric disorder that affects how people feel, think, and behave. It impacts approximately 1% ...
Should health insurance cover marijuana? Should it cover vodka? Lucky Strikes? Bacon cheeseburgers? Like all those substances ...
Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION(R) System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with ...
Bristol said it had decided to stop one of its ongoing Phase 3 trials testing an experimental blood thinner called milvexian.
Schizophrenia, a psychiatric disorder that affects how a person feels, thinks, and behaves, affects roughly 1% of the population (approximately 3.5 million people in the U.S.) and is a leading cause ...
Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION® System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with ...
A strategic and financial recalibration on psychiatric drug development brings profound implications for investors, insurers, ...
The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for ...
Arm’s Earnings Meet Expectations. Why the Stock Is Falling. Shares of Arm Holdings, whose customers include Apple, Microsoft, and Nvidia, are up over 30% this year. GE HealthCare Stock Falls Despite ...
The drug information sheets that the FDA requires companies to produce are living documents that get updated with new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback